Literature DB >> 1411331

Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration.

R M Bilder1, L Lipschutz-Broch, G Reiter, S H Geisler, D I Mayerhoff, J A Lieberman.   

Abstract

The developmental processes leading to neuropsychological deficits in schizophrenia are poorly understood. Both early developmental defects and subsequent deterioration may occur. Intelligence test profiles are often used to estimate premorbid ability and deterioration from prior levels of functioning. These characteristics were assessed in samples of first-episode (n = 51) and chronic (n = 50) schizophrenic patients. Although the groups showed few differences on tests to estimate premorbid intellectual ability, the chronic group performed worse on measures considered sensitive to deterioration. Dextral (right-handed) patients tended to have better performance; this effect was marked in the first-episode sample, especially on verbal tests. Male patients showed more evidence of deterioration than female patients. Subgroups differing in the time course of premorbid social dysfunction also differed in intelligence test profiles, suggesting that estimates of social and cognitive deterioration may have concurrent validity. The results support the hypothesis that patients differ in the course of cognitive decline and suggest that deterioration of function may follow the onset of overt psychosis in some patients. Prospective longitudinal studies of first-episode schizophrenic patients could directly test this hypothesis.

Entities:  

Mesh:

Year:  1992        PMID: 1411331     DOI: 10.1093/schbul/18.3.437

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  32 in total

1.  Cognition, schizophrenia, and the atypical antipsychotic drugs.

Authors:  H Y Meltzer; S Park; R Kessler
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

Review 2.  Measuring neuropsychological change in schizophrenia with novel antipsychotic medications.

Authors:  S E Purdon
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

Review 3.  Sources of heterogeneity in schizophrenia: the role of neuropsychological functioning.

Authors:  B E Seaton; G Goldstein; D N Allen
Journal:  Neuropsychol Rev       Date:  2001-03       Impact factor: 7.444

4.  Neurocognition in schizophrenia: a 20-year multi-follow-up of the course of processing speed and stored knowledge.

Authors:  Aaron Bonner-Jackson; Linda S Grossman; Martin Harrow; Cherise Rosen
Journal:  Compr Psychiatry       Date:  2010-03-29       Impact factor: 3.735

Review 5.  Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes.

Authors:  Beth E Snitz; Angus W Macdonald; Cameron S Carter
Journal:  Schizophr Bull       Date:  2005-09-15       Impact factor: 9.306

Review 6.  Toward a model of memory enhancement in schizophrenia: glucose administration and hippocampal function.

Authors:  William S Stone; Larry J Seidman
Journal:  Schizophr Bull       Date:  2007-05-15       Impact factor: 9.306

Review 7.  [Cognitive disorders in schizophrenic patients].

Authors:  H-P Volz; F Reischies; M Riedel
Journal:  Nervenarzt       Date:  2010-01       Impact factor: 1.214

8.  Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study.

Authors:  D M Censits; J D Ragland; R C Gur; R E Gur
Journal:  Schizophr Res       Date:  1997-04-11       Impact factor: 4.939

9.  The relationship between IQ, memory, executive function, and processing speed in recent-onset psychosis: 1-year stability and clinical outcome.

Authors:  Verity C Leeson; Thomas R E Barnes; Masuma Harrison; Elizabeth Matheson; Isobel Harrison; Stanley H Mutsatsa; Maria A Ron; Eileen M Joyce
Journal:  Schizophr Bull       Date:  2008-08-04       Impact factor: 9.306

10.  The impact of executive function on emotion recognition and emotion experience in patients with schizophrenia.

Authors:  Seung Jae Lee; Hae-Kook Lee; Yong-Sil Kweon; Chung Tai Lee; Kyoung-Uk Lee
Journal:  Psychiatry Investig       Date:  2009-06-23       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.